Angle PLC Announces Research on HER2 Assay Kit Showcased at AACR
ANGLE plc presented new data at the AACR Special Conference regarding their development of a Parsortix-based HER2 assay kit in collaboration with BioView. The study, involving 43 metastatic breast cancer patients, showcased a scoring system for HER2 expression in circulating tumor cells (CTCs). The research demonstrated that some initially HER2-negative patients became HER2-positive over time, as detected through CTC analysis. This blood-based test could enable identification of patients who might benefit from HER2-targeted therapies, particularly important since approximately 80% of breast cancer patients are initially categorized as HER2-negative, but their status can change over time.
ANGLE plc ha presentato nuovi dati alla Conferenza Speciale AACR riguardanti lo sviluppo di un kit per il test HER2 basato su Parsortix in collaborazione con BioView. Lo studio, che ha coinvolto 43 pazienti con carcinoma mammario metastatico, ha mostrato un sistema di punteggio per l'espressione di HER2 nelle cellule tumorali circolanti (CTC). La ricerca ha dimostrato che alcuni pazienti inizialmente negativi per HER2 sono diventati positivi nel tempo, come rilevato attraverso l'analisi delle CTC. Questo test basato sul sangue potrebbe consentire l'identificazione dei pazienti che potrebbero trarre beneficio da terapie mirate a HER2, particolarmente importante poiché circa l'80% dei pazienti con cancro al seno sono inizialmente classificati come HER2-negativi, ma il loro stato può cambiare nel tempo.
ANGLE plc presentó nuevos datos en la Conferencia Especial de la AACR sobre el desarrollo de un kit de ensayo HER2 basado en Parsortix en colaboración con BioView. El estudio, que involucró a 43 pacientes con cáncer de mama metastásico, mostró un sistema de puntuación para la expresión de HER2 en células tumorales circulantes (CTC). La investigación demostró que algunos pacientes inicialmente negativos para HER2 se volvieron positivos con el tiempo, según lo detectado a través del análisis de CTC. Esta prueba basada en sangre podría permitir la identificación de pacientes que podrían beneficiarse de terapias dirigidas a HER2, lo cual es particularmente importante ya que aproximadamente el 80% de los pacientes con cáncer de mama son inicialmente categorizados como HER2-negativos, pero su estado puede cambiar con el tiempo.
ANGLE plc는 BioView와 협력하여 개발 중인 Parsortix 기반 HER2 검사 키트에 대한 새로운 데이터를 AACR 특별 회의에서 발표했습니다. 이 연구에는 43명의 전이성 유방암 환자가 포함되었으며, 순환 종양 세포(CTC)에서 HER2 발현을 평가하는 점수 체계를 소개했습니다. 연구 결과, 일부 초기 HER2 음성 환자들이 시간이 지남에 따라 HER2 양성으로 전환되는 것을 발견했으며, 이는 CTC 분석을 통해 검출되었습니다. 이 혈액 기반 검사는 HER2 표적 치료의 혜택을 받을 수 있는 환자를 식별하는 데 도움을 줄 수 있으며, 유방암 환자의 약 80%가 처음에는 HER2 음성으로 분류되지만 시간이 지남에 따라 상태가 변할 수 있다는 점에서 특히 중요합니다.
ANGLE plc a présenté de nouvelles données lors de la Conférence Spéciale AACR concernant le développement d'un kit de test HER2 basé sur Parsortix en collaboration avec BioView. L'étude, impliquant 43 patients atteints de cancer du sein métastatique, a présenté un système de notation pour l'expression de HER2 dans les cellules tumorales circulantes (CTC). La recherche a démontré que certains patients initialement négatifs pour HER2 sont devenus positifs au fil du temps, comme le détecte l'analyse des CTC. Ce test basé sur le sang pourrait permettre d'identifier les patients susceptibles de bénéficier des thérapies ciblées sur HER2, ce qui est particulièrement important puisque environ 80 % des patients atteints de cancer du sein sont initialement classés comme HER2-négatifs, mais leur statut peut évoluer avec le temps.
ANGLE plc präsentierte neue Daten auf der AACR-Sonderkonferenz bezüglich der Entwicklung eines Parsortix-basierten HER2-Testkits in Zusammenarbeit mit BioView. Die Studie, an der 43 Patienten mit metastasiertem Brustkrebs teilnahmen, zeigte ein Bewertungssystem für die HER2-Expression in zirkulierenden Tumorzellen (CTC). Die Forschung zeigte, dass einige ursprünglich HER2-negative Patienten im Laufe der Zeit HER2-positiv wurden, was durch die CTC-Analyse festgestellt wurde. Dieser blutbasierte Test könnte die Identifizierung von Patienten ermöglichen, die von HER2-zielgerichteten Therapien profitieren könnten, was besonders wichtig ist, da etwa 80% der Brustkrebspatienten anfänglich als HER2-negativ eingestuft werden, sich ihr Status jedoch im Laufe der Zeit ändern kann.
- Development of innovative blood-based HER2 testing system that allows repeated monitoring
- Successful demonstration of HER2 status changes in patients through CTC analysis
- Potential to identify additional patients eligible for HER2-targeted therapies
- None.
RESULTS FROM WORK TO DEVELOP A PARSORTIX-BASED Her2 assay KIT SHOWCASED AT INTERNATIONAL LIQUID BIOPSY CONFERENCE
Parsortix-based HER2 kit being developed to provide an optimised, easily implemented, solution to enable product customers to undertake longitudinal, repeat assessment of HER2 status in breast cancer
GUILDFORD, SURREY / ACCESSWIRE / November 15, 2024 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, is pleased to announce the publication of new data at the American Association for Cancer Research (AACR) Special Conference in Cancer Research in San Diego, US from 13 to 16 November 2024.
ANGLE is presenting a poster entitled the "Development of a scoring system to classify HER2 protein expression in Circulating Tumor Cells through immunofluorescence following isolation using Parsortix® instruments" and reports on progress of the Company's co-development programme with BioView.
Using the high throughput BioView Allegro Plus microscope, ANGLE and BioView are developing an end-to-end assay kit for the evaluation of HER2 gene amplification and protein expression in circulating tumour cells (CTCs) harvested using the Parsortix system from the blood of metastatic breast cancer (MBC) patients.
Results presented showcase the development of a scoring system for HER2 expression, which could be implemented alongside the current standard of care which uses tumour tissue for HER2 assessment. The workflow was assessed in a cohort of 43 MBC patients. The study identified cases where HER2 status had changed over time and patients who were initially HER2 negative had, in the time elapsed since tissue biopsy, become HER2 positive based on their CTC analysis.
Approximately
BioView's Chief Scientific Officer, Chassidy Johnson, commented:
"The results ANGLE will present from our co-development work at the AACR Special Conference in Cancer Research are an important milestone in our development programme. The results highlight the ability and robust analytical performance of the developed HER2 CTC assay to detect ranges of HER2 expression therefore potentially identifying patients that could benefit from anti-HER2 therapy as well as newer HER2-targeted ADCs."
ANGLE's Chief Scientific Officer, Karen Miller, commented:
"We are pleased to present new data from our collaborative HER2 assay development programme at the AACR Special Conference in Cancer Research. This study highlights the potential for longitudinal, repeat assessment of HER2 CTC status to identify patients whose HER2 status has changed and could therefore benefit from treatment with HER2-targeted ADC or anti-HER2 therapy."
The poster is available for review at: https://angleplc.com/resources/posters/.
For further information:
ANGLE plc | +44 (0) 1483 343434 |
Berenberg (NOMAD and Broker) | +44 (0) 20 3207 7800 |
FTI Consulting |
|
For Research Use Only. Not for use in diagnostic procedures.
For Frequently Used Terms, please see the Company's website on https://angleplc.com/investor-relations/glossary/
Notes for editors
About ANGLE plc
ANGLE is a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology using a simple blood sample. ANGLE's FDA cleared and patent protected CTC harvesting technology known as the Parsortix® PC1 System enables complete downstream analysis of the sample including whole cell imaging and proteomic analysis and full genomic and transcriptomic molecular analysis.
ANGLE's commercial businesses are focusing on clinical services and diagnostic products. The clinical services business is offered through ANGLE's GCLP-compliant laboratories. Services include custom made assay development and clinical trial testing for pharma. Products include the Parsortix system, associated consumables and assays.
Over 100 peer-reviewed publications have demonstrated the performance of the Parsortix system. For more information, visit www.angleplc.com
Any reference to regulatory authorisations such as FDA clearance, CE marking or UK MHRA registration shall be read in conjunction with the full intended use of the product:
The Parsortix® PC1 system is an in vitro diagnostic device intended to enrich circulating tumor cells (CTCs) from peripheral blood collected in K2EDTA tubes from patients diagnosed with metastatic breast cancer. The system employs a microfluidic chamber (a Parsortix cell separation cassette) to capture cells of a certain size and deformability from the population of cells present in blood. The cells retained in the cassette are harvested by the Parsortix PC1 system for use in subsequent downstream assays. The end user is responsible for the validation of any downstream assay. The standalone device, as indicated, does not identify, enumerate or characterize CTCs and cannot be used to make any diagnostic/prognostic claims for CTCs, including monitoring indications or as an aid in any disease management and/or treatment decisions.
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: ANGLE plc
View the original press release on accesswire.com
FAQ
What is the purpose of ANGLE's new HER2 assay kit presented at AACR 2024?
How many patients were included in ANGLE's (ANPCY) HER2 assay study?
What percentage of breast cancer patients are initially HER2-negative according to ANGLE's presentation?
Who is ANGLE plc (ANPCY) collaborating with on the HER2 assay development?
